Publications

  1. Lheureux S, Cristea MC, Bruce JP, Garg S, Cabanero M, Mantia-Smaldone G, Olawaiye AB, Ellard SL, Weberpals JI, Wahner Hendrickson AE, Fleming GF, Welch S, Dhani NC, Stockley T, Rath P, Karakasis K, Jones GN, Jenkins S, Rodriguez-Canales J, Tracy M, Tan Q, Bowering V, Udagani S, Wang L, Kunos CA, Chen E, Pugh TJ, Oza AM. Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021 Jan 23; 397 (10271):281-292
    View PubMed
  2. Colon-Otero G, Zanfagnin V, Hou X, Foster NR, Asmus EJ, Wahner Hendrickson A, Jatoi A, Block MS, Langstraat CL, Glaser GE, Dinh TA, Robertson MW, Camoriano JK, Butler KA, Copland JA, Weroha SJ. Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers. ESMO Open. 2020 Oct; 5 (5):e000926
    View PubMed
  3. Konstantinopoulos PA, Cheng SC, Wahner Hendrickson AE, Penson RT, Schumer ST, Doyle LA, Lee EK, Kohn EC, Duska LR, Crispens MA, Olawaiye AB, Winer IS, Barroilhet LM, Fu S, McHale MT, Schilder RJ, Farkkila A, Chowdhury D, Curtis J, Quinn RS, Bowes B, D'Andrea AD, Shapiro GI, Matulonis UA. Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2020 Jul; 21 (7):957-968 Epub 2020 June 15
    View PubMed
  4. Smith C, Hendrickson AW, Grudem M, Klampe C, Deering E, Jatoi A. Loratadine for Paclitaxel-Induced Myalgias and Arthralgias. Am J Hosp Palliat Care. 2020 Mar; 37 (3):235-238 Epub 2019 July 17
    View PubMed
  5. Marshall AL, Dines V, Wahner Hendrickson A, Warsame R, Thanarajasingam G, Thompson C, Petterson T, Wolanskyj-Spinner A. Parental health in fellowship trainees: Fellows' satisfaction with current policies and interest in innovation. Womens Health (Lond). 2020 Jan-Dec; 16:1745506520949417
    View PubMed
  6. Kanakkanthara A, Kurmi K, Ekstrom TL, Hou X, Purfeerst ER, Heinzen EP, Correia C, Huntoon CJ, O'Brien D, Wahner Hendrickson AE, Dowdy SC, Li H, Oberg AL, Hitosugi T, Kaufmann SH, Weroha SJ, Karnitz LM. BRCA1 Deficiency Upregulates NNMT, Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents. Cancer Res. 2019 Dec 1; 79 (23):5920-5929 Epub 2019 Oct 16
    View PubMed
  7. Wahner-Hendrickson A, Bundrick JB. Clinical Pearls in Oncology 2019. Dis Mon. 2019 Nov; 65 (11):100863 Epub 2019 June 22
    View PubMed
  8. Vinayak S, Tolaney SM, Schwartzberg L, Mita M, McCann G, Tan AR, Wahner-Hendrickson AE, Forero A, Anders C, Wulf GM, Dillon P, Lynce F, Zarwan C, Erban JK, Zhou Y, Buerstatte N, Graham JR, Arora S, Dezube BJ, Telli ML. Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer. JAMA Oncol. 2019 Jun 13 Epub 2019 June 13
    View PubMed
  9. Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, Wahner Hendrickson AE, Azodi M, DiSilvestro P, Oza AM, Cristea M, Berek JS, Chan JK, Rimel BJ, Matei DE, Li Y, Sun K, Luptakova K, Matulonis UA, Monk BJ. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019 May; 20 (5):636-648 Epub 2019 Apr 01
    View PubMed
  10. Hurley RM, Wahner Hendrickson AE, Visscher DW, Ansell P, Harrell MI, Wagner JM, Negron V, Goergen KM, Maurer MJ, Oberg AL, Meng XW, Flatten KS, De Jonge MJA, Van Herpen CD, Gietema JA, Koornstra RHT, Jager A, den Hollander MW, Dudley M, Shepherd SP, Swisher EM, Kaufmann SH. 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer. Gynecol Oncol. 2019 Apr; 153 (1):127-134 Epub 2019 Jan 25
    View PubMed
  11. Balko RA, Hendrickson AW, Grudem ME, Klampe CM, Jatoi A. Can Poly (ADP-Ribose) Polymerase Inhibitors Palliate Paclitaxel-Induced Peripheral Neuropathy in Patients With Cancer? Am J Hosp Palliat Care. 2019 Jan; 36 (1):72-75 Epub 2018 July 08
    View PubMed
  12. Moore KN, Secord AA, Geller M, Miller DS, Cloven NG, Fleming GF, Wahner Hendrickson AE, Azodi M, DiSilvestro P, Oza A, Cristea M, Berek JS, Chan JK, Rimel BJ, Li Y, Luptakova K, Clark R, Matulonis UA, Monk BJ. QUADRA: A phase II, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) in 4th or later line of therapy: Results from the tBRCAmut subset. Ann Oncol. 2018 Oct; 29 Suppl 8:viii337
    View PubMed
  13. Wahner Hendrickson AE, Costello B, Jewell A, Kennedy V, Fleming G, Corr B, Taylor SE, Lea J, Reid J, Swisher E, Satele D, Allred J, Lensing J, Ivy SP, Erlichman C, Adjei AA, Kaufmann S. A phase II clinical trial of veliparib and topotecan in patients with platinum resistant ovarian cancer. Ann Oncol. 2018 Oct; 29 Suppl 8:viii357
    View PubMed
  14. Doles JD, Hogan KA, O'Connor J, Wahner Hendrickson AE, Huston O, Jatoi A. Does the Poly (ADP-Ribose) Polymerase Inhibitor Veliparib Merit Further Study for Cancer-Associated Weight Loss? Observations and Conclusions from Sixty Prospectively Treated Patients. J Palliat Med. 2018 Sep; 21 (9):1334-1338 Epub 2018 May 24
    View PubMed
  15. Gast KC, Viscuse PV, Nowsheen S, Haddad TC, Mutter RW, Wahner Hendrickson AE, Couch FJ, Ruddy KJ. Cardiovascular Concerns in BRCA1 and BRCA2 Mutation Carriers. Curr Treat Options Cardiovasc Med. 2018 Mar 1; 20 (2):18 Epub 2018 Mar 01
    View PubMed
  16. Wahner Hendrickson AE, Menefee ME, Hartmann LC, Long HJ, Northfelt DW, Reid JM, Boakye-Agyeman F, Kayode O, Flatten KS, Harrell MI, Swisher EM, Poirer GG, Satele D, Allred J, Lensing JL, Allred JB, Chen A, Ji J, Zang Y, Erlichman C, Haluska P, Kaufmann SH. A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors. Clin Cancer Res. 2018 Feb 15; 24 (4):744-752 Epub 2017 Nov 14
    View PubMed
  17. Wahner Hendrickson AE, Kaufmann SH, Swisher EM. Doubling Down on BRCA-Mutated Cancer. Trends Cancer 2017 Nov; 3 (11):743-744 Epub 2017 Sept 29
    View PubMed
  18. Colon-Otero G, Weroha SJ, Foster NR, Haluska P, Hou X, Wahner-Hendrickson AE, Jatoi A, Block MS, Dinh TA, Robertson MW, Copland JA. Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers. Gynecol Oncol. 2017 Jul; 146 (1):64-68 Epub 2017 Apr 28
    View PubMed
  19. Yun S, Vincelette ND, Green MR, Wahner Hendrickson AE, Abraham I. Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials. Cancer Med. 2016 Jul; 5 (7):1481-91 Epub 2016 May 11
    View PubMed
  20. Yun S, Vincelette ND, Knorr KL, Almada LL, Schneider PA, Peterson KL, Flatten KS, Dai H, Pratz KW, Hess AD, Smith BD, Karp JE, Hendrickson AE, Fernandez-Zapico ME, Kaufmann SH. 4EBP1/c-MYC/PUMA and NF-kappaB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells. Blood. 2016 Jun 2; 127 (22):2711-22 Epub 2016 Feb 25
    View PubMed
  21. Wahner Hendrickson AE, Hawthorne KM, Goode EL, Kalli KR, Goergen KM, Bakkum-Gamez JN, Cliby WA, Keeney GL, Visscher DW, Tarabishy Y, Oberg AL, Hartmann LC, Maurer MJ. Assessment of published models and prognostic variables in epithelial ovarian cancer at Mayo Clinic. Gynecol Oncol. 2015 Apr; 137 (1):77-85 Epub 2015 Jan 22
    View PubMed
  22. Jatoi A, Radecki Breitkopf C, Foster NR, Block MS, Grudem M, Wahner Hendrickson A, Carlson RE, Barrette B, Karlin N, Fields AP. A mixed-methods feasibility trial of protein kinase C iota inhibition with auranofin in asymptomatic ovarian cancer patients. Oncology. 2015; 88 (4):208-13 Epub 2014 Dec 06
    View PubMed
  23. Schenk E, Hendrickson AE, Northfelt D, Toft DO, Ames MM, Menefee M, Satele D, Qin R, Erlichman C. Phase I study of tanespimycin in combination with bortezomib in patients with advanced solid malignancies. Invest New Drugs. 2013 Oct; 31 (5):1251-6 Epub 2013 Mar 31
    View PubMed
  24. Huntoon CJ, Flatten KS, Wahner Hendrickson AE, Huehls AM, Sutor SL, Kaufmann SH, Karnitz LM. ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status. Cancer Res. 2013 Jun 15; 73 (12):3683-91 Epub 2013 Apr 02
    View PubMed
  25. Hendrickson AE, Oberg AL, Glaser G, Camoriano JK, Peethambaram PP, Colon-Otero G, Erlichman C, Ivy SP, Kaufmann SH, Karnitz LM, Haluska P. A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma. Gynecol Oncol. 2012 Feb; 124 (2):210-5 Epub 2011 Nov 01
    View PubMed
  26. Gupta M, Hendrickson AE, Yun SS, Han JJ, Schneider PA, Koh BD, Stenson MJ, Wellik LE, Shing JC, Peterson KL, Flatten KS, Hess AD, Smith BD, Karp JE, Barr S, Witzig TE, Kaufmann SH. Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies. Blood. 2012 Jan 12; 119 (2):476-87 Epub 2011 Nov 11
    View PubMed
  27. Lewis MA, Hendrickson AW, Moynihan TJ. Oncologic emergencies: Pathophysiology, presentation, diagnosis, and treatment. CA Cancer J Clin. 2011 Sep-Oct; 61: (5)287-314.
    View PubMed
  28. Behl D, Hendrickson AW, Moynihan TJ. Oncologic emergencies. Crit Care Clin. 2010 Jan; 26(1):181-205.
    View PubMed
  29. Hendrickson AW, Haluska P. Resistance pathways relevant to insulin-like growth factor-1 receptor-targeted therapy. Curr Opin Investig Drugs. 2009 Oct; 10(10):1032-40.
    View PubMed
  30. Wahner Hendrickson AE, Haluska P, Schneider PA, Loegering DA, Peterson KL, Attar R, Smith BD, Erlichman C, Gottardis M, Karp JE, Carboni JM, Kaufmann SH. Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro. Cancer Res. 2009 Oct 1; 69 (19):7635-43 Epub 2009 Sept 29
    View PubMed
  31. Black SM, Grehan JF, Rivard AL, Benson BA, Wahner AE, Koch AE, Levay-Young BK, Dalmasso AP. Porcine endothelial cells and iliac arteries transduced with AdenoIL-4 are intrinsically protected, through Akt activation, against immediate injury caused by human complement. J Immunol. 2006 Nov 15; 177(10):7355-63.
    View PubMed
  32. Xu Y, Wahner AE, Nguyen PL. Progression of chronic myeloid leukemia to blast crisis during treatment with imatinib mesylate. Arch Pathol Lab Med. 2004 Sep; 128(9):980-5.
    View PubMed
  33. Wallace PK, Kaufman PA, Lewis LD, Keler T, Givan AL, Fisher JL, Waugh MG, Wahner AE, Guyre PM, Fanger MW, Ernstoff MS. Bispecific antibody-targeted phagocytosis of HER-2/neu expressing tumor cells by myeloid cells activated in vivo. J Immunol Methods. 2001 Feb 1; 248(1-2):167-82.
    View PubMed
  34. Sulahian TH, Hogger P, Wahner AE, Wardwell K, Goulding NJ, Sorg C, Droste A, Stehling M, Wallace PK, Morganelli PM, Guyre PM. Human monocytes express CD163, which is upregulated by IL-10 and identical to p155. Cytokine. 2000 Sep; 12(9):1312-21.
    View PubMed
  35. Wagner UG, Kurtin PJ, Wahner A, Brackertz M, Berry DJ, Goronzy JJ, Weyand CM. The role of CD8+ CD40L+ T cells in the formation of germinal centers in rheumatoid synovitis. J Immunol. 1998 Dec 1; 161 (11):6390-7
    View PubMed